Dashboard
1
High Management Efficiency with a high ROCE of 22.43%
2
High Debt Company with a Debt to Equity ratio (avg) at times
3
The company has declared Negative results for the last 3 consecutive quarters
4
With ROE of 17.05%, it has a Expensive valuation with a 2.91 Price to Book Value
5
Underperformed the market in the last 1 year
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-2.94%
0%
-2.94%
6 Months
1.33%
0%
1.33%
1 Year
1.2%
0%
1.2%
2 Years
-17.57%
0%
-17.57%
3 Years
-17.03%
0%
-17.03%
4 Years
-47.69%
0%
-47.69%
5 Years
-13.86%
0%
-13.86%
Dermapharm Holding SE for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
8.81%
EBIT Growth (5y)
8.82%
EBIT to Interest (avg)
12.81
Debt to EBITDA (avg)
2.01
Net Debt to Equity (avg)
1.38
Sales to Capital Employed (avg)
0.84
Tax Ratio
35.83%
Dividend Payout Ratio
42.59%
Pledged Shares
0
Institutional Holding
0.12%
ROCE (avg)
22.43%
ROE (avg)
27.04%
Valuation key factors
Factor
Value
P/E Ratio
17
Industry P/E
Price to Book Value
2.91
EV to EBIT
12.16
EV to EBITDA
8.64
EV to Capital Employed
1.81
EV to Sales
2.21
PEG Ratio
0.83
Dividend Yield
NA
ROCE (Latest)
14.86%
ROE (Latest)
17.05%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Bullish
Moving Averages
Mildly Bearish (Daily)
KST
Bullish
Mildly Bullish
Dow Theory
Mildly Bullish
Mildly Bullish
OBV
No Trend
No Trend
Shareholding Snapshot : Dec 2023
Shareholding Compare (%holding) 
Majority shareholders
Foreign Institutions
Domestic Funds
Held in 0 Schemes (0%)
Foreign Institutions
Held by 1 Foreign Institutions (0.12%)
Strategic Entities with highest holding
Highest Public shareholder
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ
Jun'25
Mar'25
Change(%)
Net Sales
272.10
302.40
-10.02%
Operating Profit (PBDIT) excl Other Income
64.80
79.80
-18.80%
Interest
13.20
12.90
2.33%
Exceptional Items
0.00
0.00
Consolidate Net Profit
20.90
33.20
-37.05%
Operating Profit Margin (Excl OI)
163.50%
197.70%
-3.42%
USD in Million.
Net Sales
QoQ Growth in quarter ended Jun 2025 is -10.02% vs 4.02% in Mar 2025
Consolidated Net Profit
QoQ Growth in quarter ended Jun 2025 is -37.05% vs 74.74% in Mar 2025
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
1,180.80
1,135.40
4.00%
Operating Profit (PBDIT) excl Other Income
297.90
304.90
-2.30%
Interest
63.40
59.50
6.55%
Exceptional Items
1.80
-46.40
103.88%
Consolidate Net Profit
111.70
60.50
84.63%
Operating Profit Margin (Excl OI)
175.60%
176.50%
-0.09%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is 4.00% vs 10.79% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is 84.63% vs -54.37% in Dec 2023
About Dermapharm Holding SE 
Dermapharm Holding SE
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






